4//SEC Filing
Sagent Pharmaceuticals, Inc. 4
Accession 0000904454-15-000676
CIK 0001369786operating
Filed
Nov 3, 7:00 PM ET
Accepted
Nov 4, 6:36 PM ET
Size
19.5 KB
Accession
0000904454-15-000676
Insider Transaction Report
Form 4
Transactions
- Sale
Common Stock
2015-11-02$16.87/sh−680$11,471→ 29,725 total(indirect: See footnote (4)) - Sale
Common Stock
2015-11-03$16.32/sh−66,793$1,090,062→ 3,990,750 total(indirect: See footnote (5)) - Sale
Common Stock
2015-11-04$15.45/sh−3,898$60,224→ 25,337 total(indirect: See footnote (8)) - Sale
Common Stock
2015-11-02$16.87/sh−92,843$1,566,215→ 4,057,543 total(indirect: See footnote (3)) - Sale
Common Stock
2015-11-03$16.32/sh−490$7,997→ 29,235 total(indirect: See footnote (6)) - Sale
Common Stock
2015-11-04$15.45/sh−532,119$8,221,239→ 3,458,631 total(indirect: See footnote (7))
Vivo Ventures Fund VI, L.P.
10% Owner
Transactions
- Sale
Common Stock
2015-11-02$16.87/sh−92,843$1,566,215→ 4,057,543 total(indirect: See footnote (3)) - Sale
Common Stock
2015-11-03$16.32/sh−66,793$1,090,062→ 3,990,750 total(indirect: See footnote (5)) - Sale
Common Stock
2015-11-04$15.45/sh−532,119$8,221,239→ 3,458,631 total(indirect: See footnote (7)) - Sale
Common Stock
2015-11-04$15.45/sh−3,898$60,224→ 25,337 total(indirect: See footnote (8)) - Sale
Common Stock
2015-11-02$16.87/sh−680$11,471→ 29,725 total(indirect: See footnote (4)) - Sale
Common Stock
2015-11-03$16.32/sh−490$7,997→ 29,235 total(indirect: See footnote (6))
Vivo Ventures VI, LLC
10% Owner
Transactions
- Sale
Common Stock
2015-11-02$16.87/sh−92,843$1,566,215→ 4,057,543 total(indirect: See footnote (3)) - Sale
Common Stock
2015-11-03$16.32/sh−66,793$1,090,062→ 3,990,750 total(indirect: See footnote (5)) - Sale
Common Stock
2015-11-04$15.45/sh−532,119$8,221,239→ 3,458,631 total(indirect: See footnote (7)) - Sale
Common Stock
2015-11-04$15.45/sh−3,898$60,224→ 25,337 total(indirect: See footnote (8)) - Sale
Common Stock
2015-11-02$16.87/sh−680$11,471→ 29,725 total(indirect: See footnote (4)) - Sale
Common Stock
2015-11-03$16.32/sh−490$7,997→ 29,235 total(indirect: See footnote (6))
Footnotes (8)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.59 to $17.14 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $17.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
- [F3]Includes 4,057,543 shares held of record by Vivo Ventures Fund VI, L.P. ("Fund VI"). Vivo Ventures VI, LLC, the sole general partner of Fund VI, may be deemed to be the beneficial owner of the shares held by Fund VI. Vivo Ventures VI, LLC hereby disclaims any beneficial ownership of any shares directly held by Fund VI, except to the extent of its pecuniary interest therein.
- [F4]Includes 29,725 shares held of record by Vivo Ventures VI Affiliates Fund, L.P. ("VI Affiliates Fund"). Vivo Ventures VI, LLC, the sole general partner of VI Affiliates Fund, may be deemed to be the beneficial owner of the shares held by VI Affiliates Fund. Vivo Ventures VI, LLC hereby disclaims any beneficial ownership of any shares directly held by VI Affiliates Fund, except to the extent of its pecuniary interest therein.
- [F5]Includes 3,990,750 shares held of record by Vivo Ventures Fund VI, L.P. ("Fund VI"). Vivo Ventures VI, LLC, the sole general partner of Fund VI, may be deemed to be the beneficial owner of the shares held by Fund VI. Vivo Ventures VI, LLC hereby disclaims any beneficial ownership of any shares directly held by Fund VI, except to the extent of its pecuniary interest therein.
- [F6]Includes 29,235 shares held of record by Vivo Ventures VI Affiliates Fund, L.P. ("VI Affiliates Fund"). Vivo Ventures VI, LLC, the sole general partner of VI Affiliates Fund, may be deemed to be the beneficial owner of the shares held by VI Affiliates Fund. Vivo Ventures VI, LLC hereby disclaims any beneficial ownership of any shares directly held by VI Affiliates Fund, except to the extent of its pecuniary interest therein.
- [F7]Includes 3,458,631shares held of record by Vivo Ventures Fund VI, L.P. ("Fund VI"). Vivo Ventures VI, LLC, the sole general partner of Fund VI, may be deemed to be the beneficial owner of the shares held by Fund VI. Vivo Ventures VI, LLC hereby disclaims any beneficial ownership of any shares directly held by Fund VI, except to the extent of its pecuniary interest therein.
- [F8]Includes 25,337 shares held of record by Vivo Ventures VI Affiliates Fund, L.P. ("VI Affiliates Fund"). Vivo Ventures VI, LLC, the sole general partner of VI Affiliates Fund, may be deemed to be the beneficial owner of the shares held by VI Affiliates Fund. Vivo Ventures VI, LLC hereby disclaims any beneficial ownership of any shares directly held by VI Affiliates Fund, except to the extent of its pecuniary interest therein.
Documents
Issuer
Sagent Pharmaceuticals, Inc.
CIK 0001369786
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001369786
Filing Metadata
- Form type
- 4
- Filed
- Nov 3, 7:00 PM ET
- Accepted
- Nov 4, 6:36 PM ET
- Size
- 19.5 KB